163 related articles for article (PubMed ID: 34079583)
1. Association of
Liu Z; Liu L; Jiao D; Guo C; Wang L; Li Z; Sun Z; Zhao Y; Han X
Front Genet; 2021; 12():669694. PubMed ID: 34079583
[No Abstract] [Full Text] [Related]
2. Bioinformatic Analysis of Immune Significance of RYR2 Mutation in Breast Cancer.
Xu Z; Xiang L; Wang R; Xiong Y; Zhou H; Gu H; Wang J; Peng L
Biomed Res Int; 2021; 2021():8072796. PubMed ID: 34888385
[TBL] [Abstract][Full Text] [Related]
3. Mutations in lysine methyltransferase 2C and PEG3 are associated with tumor mutation burden, prognosis, and antitumor immunity in pancreatic adenocarcinoma patients.
Huang Y; Liu J; Zhu X
Digit Health; 2022; 8():20552076221133699. PubMed ID: 36312851
[TBL] [Abstract][Full Text] [Related]
4. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
5.
Sun Y; Li L; Yao W; Liu X; Yang Y; Ma B; Xue D
Front Genet; 2021; 12():762160. PubMed ID: 34795697
[TBL] [Abstract][Full Text] [Related]
6. Mucin 4 mutation is associated with tumor mutation burden and promotes antitumor immunity in colon cancer patients.
Peng L; Li Y; Gu H; Xiang L; Xiong Y; Wang R; Zhou H; Wang J
Aging (Albany NY); 2021 Mar; 13(6):9043-9055. PubMed ID: 33714943
[TBL] [Abstract][Full Text] [Related]
7.
Xie X; Tang Y; Sheng J; Shu P; Zhu X; Cai X; Zhao C; Wang L; Huang X
Front Cell Dev Biol; 2021; 9():761758. PubMed ID: 34746153
[TBL] [Abstract][Full Text] [Related]
8. EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Zhu G; Pei L; Li Y; Gou X
Aging (Albany NY); 2020 Feb; 12(3):2132-2141. PubMed ID: 32012118
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of Immune-Related Multi-IncRNA Signatures Associated With Tumor Microenvironment in Esophageal Cancer.
Pang J; Pan H; Yang C; Meng P; Xie W; Li J; Li Y; Xiao SY
Front Genet; 2021; 12():722601. PubMed ID: 34659345
[TBL] [Abstract][Full Text] [Related]
10. Association between tumor mutation burden and immune infiltration in ovarian cancer.
Fan S; Gao X; Qin Q; Li H; Yuan Z; Zhao S
Int Immunopharmacol; 2020 Dec; 89(Pt A):107126. PubMed ID: 33189611
[TBL] [Abstract][Full Text] [Related]
11. Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma.
Kang K; Xie F; Mao J; Bai Y; Wang X
Front Oncol; 2020; 10():573141. PubMed ID: 33072607
[No Abstract] [Full Text] [Related]
12. CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.
Lu N; Liu J; Xu M; Liang J; Wang Y; Wu Z; Xing Y; Diao F
Int J Gen Med; 2021; 14():7647-7657. PubMed ID: 34764678
[TBL] [Abstract][Full Text] [Related]
13. Identification of Immune Subtypes of Esophageal Adenocarcinoma to Predict Prognosis and Immunotherapy Response.
Ling C; Zhou X; Gao Y; Sui X
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631431
[TBL] [Abstract][Full Text] [Related]
14. Papillary thyroid carcinoma with a high tumor mutation burden has a poor prognosis.
Xie Z; Li X; Lun Y; He Y; Wu S; Wang S; Sun J; He Y; Xin S; Zhang J
Int Immunopharmacol; 2020 Dec; 89(Pt B):107090. PubMed ID: 33091816
[TBL] [Abstract][Full Text] [Related]
15. Identification of the Immune Cell Infiltration Landscape in Hepatocellular Carcinoma to Predict Prognosis and Guide Immunotherapy.
Yang S; Cheng Y; Wang X; Wei P; Wang H; Tan S
Front Genet; 2021; 12():777931. PubMed ID: 34899862
[No Abstract] [Full Text] [Related]
16. ADRB1 was identified as a potential biomarker for breast cancer by the co-analysis of tumor mutational burden and immune infiltration.
Wang J; Zhang X; Li J; Ma X; Feng F; Liu L; Wu J; Sun C
Aging (Albany NY); 2020 Nov; 13(1):351-363. PubMed ID: 33234738
[TBL] [Abstract][Full Text] [Related]
17. An Integrative Analysis Reveals the Underlying Association Between CTNNB1 Mutation and Immunotherapy in Hepatocellular Carcinoma.
Mo Z; Wang Y; Cao Z; Li P; Zhang S
Front Oncol; 2020; 10():853. PubMed ID: 32596147
[No Abstract] [Full Text] [Related]
18. Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma.
Fu M; Huang Y; Peng X; Li X; Luo N; Zhu W; Yang F; Chen Z; Ma S; Zhang Y; Li Q; Hu G
Front Cell Dev Biol; 2022; 10():790920. PubMed ID: 35399509
[No Abstract] [Full Text] [Related]
19. Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns.
Guo X; Tang Y; Zhu W
BMC Genomics; 2018 Oct; 19(1):769. PubMed ID: 30355311
[TBL] [Abstract][Full Text] [Related]
20. Gene expression and immune infiltration in melanoma patients with different mutation burden.
Wang L; Chen F; Liu R; Shi L; Zhao G; Yan Z
BMC Cancer; 2021 Apr; 21(1):379. PubMed ID: 33836680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
